AbbVie Inc (ABBV)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 29% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 52-week positionPressing 52-week highs+30
- QualityRevenue growing 10% y/y+5
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst here is analyst activity, with Wolfe upgrades and relative-value comparisons against peers like Merck and Biogen driving recent attention rather than a fresh earnings, product, or M&A event. Continuation likelihood over the next few weeks appears modest, as analyst-driven moves often fade without a fundamental follow-through catalyst. Informational only — not financial advice.
- How AbbVie's Neuroscience Portfolio Has Transformed Over the YearsYahoo · 2026-09-16
- Is AbbVie the Best Dividend King to Buy in September?Yahoo · 2026-09-16
- Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to KnowYahoo · 2026-09-16
- Merck Stock: Is The $70 Billion Pipeline Worth the Premium?Yahoo · 2026-09-16
- Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside?Yahoo · 2026-09-15
Any AI summary is an interpretation of public news, not advice or a price target.